Home
AI
World
Politics
Health
Crime & justice
Science & technology
Social issues
Sports
Money
Entertainment
Environment/energy
Military
Culture
Weather
Media






Home
Bias Split
Public FiguresControversies

Sign Up for Our Free Newsletters
Sign Up for Our Free Newsletters

Sign Up!
Sign Up Now!

How our sliders workAboutContact UsNewsletter Archive
MediaFAQGlossaryPrivacy Policy
  1. Home

Study: Highly-Affordable 'Vaccine-Like' HIV Drug Possible

  • #Medicine & healthcare
  • #HIV
  • #Pharmaceuticals
story
JUL 2024
Image copyright: Wikimedia Commons
story last updated JUL 2024

The Spin

Narrative A

It is still too early for Gilead to be able to predict what the cost of Lenacapavir as a pre-exposure prophylaxis will be. The research presented on Tuesday has not been peer-reviewed, and thus while it is hopeful, it shouldn't be given too much weight. Gilead is working to ensure that the drug will be widely accessible in the future, but it's too early to declare this drug as an HIV panacea.

Medicalxpress

Narrative B

Gilead has the opportunity to save many lives. This drug could be a game changer in stopping the spread of HIV if it's widely available and offered at an affordable price. Cost still remains a huge barrier to access to the drug, with the price currently over 40K dollars annually for each patient. If a generic version of the drug was offered at an affordable price the world may be able to meet the 2030 goal of ending new HIV transmissions.

Guardian

Metaculus Prediction


Articles on this story

Most new HIV infections occurred outside sub-Saharan Africa for first time – UN report
GuardianJUL 2024
UN urges Gilead to 'make history' with game-changing HIV drug
Raw StoryJUL 2024